Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Fulgent Genetics, |
RCV005006529 | SCV005640547 | likely pathogenic | Polycystic kidney disease, adult type | 2024-05-31 | criteria provided, single submitter | clinical testing | |
3billion | RCV005006529 | SCV005904615 | uncertain significance | Polycystic kidney disease, adult type | 2023-09-18 | criteria provided, single submitter | clinical testing | The variant is not observed in the gnomAD v2.1.1 dataset. Predicted Consequence/Location: Missense variant Same nucleotide change resulting in same amino acid change has been previously reported to be associated with PKD1-related disorder (PMID: 31740684). The variant has been observed in at least two similarly affected unrelated individuals (PMID: 31740684). However, the evidence of pathogenicity is insufficient at this time. Therefore, this variant is classified as VUS according to the recommendation of ACMG/AMP guideline. |
Prevention |
RCV004739976 | SCV005353963 | uncertain significance | PKD1-related disorder | 2024-07-18 | no assertion criteria provided | clinical testing | The PKD1 c.1391T>C variant is predicted to result in the amino acid substitution p.Leu464Pro. This variant has been reported in two families undergoing genetic testing for autosomal dominant polycystic kidney disease by targeted exome sequencing (Table S6C, Family ID 41 and 306, Kim et al 2019. PubMed ID: 31740684). This variant has not been reported in a large population database, indicating this variant is rare. Although we suspect that this variant may be pathogenic, at this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. |